2-Tert-butyl-3-ethyloxirane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: 2-Tert-butyl-3-ethyloxirane
• 化学式: C₈H₁₆O
• 分子量: 128.21
• InChiKey: WIDDJCJBYBUXDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  反式-2,2-二甲基-3-己烯 、 methyl diphenylhydroperoxyacetate 生成 2-Tert-butyl-3-ethyloxirane
  参考文献：
  名称：

  REBEK J. JR.; MCCREADY R.; WOLAK R., J. CHEM. SOC. CHEM. COMMUN., 1980, NO 15, 705-706

  摘要：

  DOI：

文献信息

• Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
  申请人：Farmer J. Luc

  公开号：US20080045480A1

  公开（公告）日：2008-02-21

  The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.

  本发明涉及一种抑制丝氨酸蛋白酶活性的肽类类似物化合物，特别是抑制丙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰丙型肝炎病毒的生命周期来发挥作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗患有HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患有HCV感染的患者的方法。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Pitlik Janos

  公开号：US20100173851A1

  公开（公告）日：2010-07-08

  The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒NS3-NS4A蛋白酶活性的化合物。因此，它们通过干扰丙型肝炎病毒的生命周期发挥作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于治疗HCV感染的患者的给药。本发明还涉及通过给予含有本发明化合物的组合物来治疗患者的HCV感染的方法。本发明还涉及制备这些化合物的方法。
• NOVEL NUCLEOSIDE PHOSPHONATES AND ANALOGS
  申请人：Dong Steven

  公开号：US20130018018A1

  公开（公告）日：2013-01-17

  Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are nucleoside phosphonates and esters thereof.

  本文提供了用于治疗、预防或缓解与病毒感染和/或细胞增殖相关的各种医学疾病的化合物和组合物。此处提供的化合物是核苷酸磷酸酯及其酯类。
• REBEK, J. ,JR.;MARSHALL, L.;WOLAK, R.;MCMANIS, J., J. AMER. CHEM. SOC., 1984, 106, N 4, 1170-1171
  作者：REBEK, J. ,JR.、MARSHALL, L.、WOLAK, R.、MCMANIS, J.

  DOI：——

  日期：——
• Polyene polyketides, processes for their production and their use as a pharmaceutical
  申请人：Zazopoulos Emmanuel

  公开号：US20070275436A1

  公开（公告）日：2007-11-29

  This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains of Streptomyces aizunensis ; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of Streptomyces aizunensis used to produce these compounds, to the use of these compounds and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. The invention also relates to pharmaceutical compositions comprising these novel polyketides or a pharmaceutically acceptable salts or derivatives thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides.